Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

Journal of Crohn's and Colitis

Volumn 7, Issue 4, 2013, Pages 301-307

  Andrisani, G ^a   Frasca, D ^b   Romero, M ^b   Armuzzi, A ^a   Felice, C ^a   Marzo, M ^a   Pugliese, D ^a   Papa, A ^a   Mocci, G ^a   De Vitis, I ^a   Rapaccini, G L ^a   Blomberg, B B ^b   Guidi, L ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anti TNF agents; H1N1 influenza vaccine; Immunosuppression; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; INFLUENZA VACCINE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFECT; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GEOMETRIC MEAN TITER; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; ULCERATIVE COLITIS; VIRUS IMMUNITY;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875241300     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.05.011     Document Type: Article

References (41)

1. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cézard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
2. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nuñez G., Cho J.H. A frameshift mutation in NOD2 assoiated with susceptibily to Crohn's disease. Nature 2001, 411:603-606.
3. Baldassano R.N., Bradfield J.P., Monos D.S., Kim C.E., Glessner J.T., Casalunovo T., et al. Association of variants of the interleuckin-23 receptor gene with susceptibility to pediatric Crohn's disease. Clin Gastroenterol Hepatol 2007, 5:972-976.
4. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
5. Rau R., Fitzhugh C.D., Baird K., Cortez K.J., Li L., Fischer S.H., et al. Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy. Pediatr Infect Dis J 2008, 27:265-268.
6. Deutsh D.E., Olson A.D., Kraker S., Dickinson C.J. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr 1995, 20:351-353.
7. Korelitz B.I., Fuller S.R., Warman J.I., Goldberg M.D. Shingles during the course of treatment with 6 mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999, 94:424-426.
8. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
9. Fraser C., Donnelly C.A., Cauchemez S., Van Kerkhove M.D., Hollingsworth T.D., Griffin J., et al. Pandemic potential of a strain of influenza A (H1N1) virus in humans. Science Jun 19 2009, 324(5934):1557-1561. [Epub 2009 May 11].
10. Dowood F.S., Jaiun S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
11. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(2):179-186.
12. Kelly H., Grant K., Williams S., Smith D. H1N1 swine origin influenza infection in the United States and Europe in 2009 may be similar to H1N1 seasonal influenza infection in two Australian states in 2007 and 2008. Influenza Other Respi Viruses 2009, 3(4):183-188.
13. Sands B.E., Cuffari C., Katz J., Kugathasan S., Onken J., Vitek C., et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004 Sep, 10(5):677-692.
14. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis Jun 2009, 3(2):47-91.
15. Rahier J.F., Yazdanpanah Y., Viget N., Viget N., Travis S., Colombel J.F. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther Jan 2010, 31(1):5-10.
16. Mamula P., Markowitz J.E., Piccoli D.A., Klimov A., Cohen L., Baldassano R.N. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:851-856.
17. Lu Y., Jacobson D.L., Ashworth L.A., Grand R.J., Meyer A.L., McNeal M.M., et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol Feb 2009, 104(2):444-453.
18. Cullen G., Bader C., Korzenik J.R., Sands B.E. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut Mar 2012, 61(3):385-391. Epub 2011 Jul 13.
19. Gelinck L.B., van der Bijl A.E., Beyer W.E., Visser L.G., Huizinga T.W., van Hogezand R.A., et al. The effect of anti-tumor necrosis factor alpha treatment on the antibody response top influenza vaccination. Ann Rheum Dis 2008, 67:713-716.
20. Molnár T., Farkas K., Jankovics I., Melles M., Nagy F., Szepes Z., et al. Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy. Am J Gastroenterol 2011 Feb, 106(2):370-372.
21. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med Apr 15 2010, 362(15):1383-1395.
22. Panaccione R., Ghosh S., Middleton S. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J Crohns Colitis Feb 2011, 5(1):S8.
23. Satsangi J., Silverberg M.S., Vermeire S., Colombel JFl. The Montreal classification of IBD: controversies, consensus, and implications. Gut 2006, 55:749-753.
24. Lewis J.D., Chuai S., Nessel L., Lichtenstein G.R., Aberra F.N., Ellenberg J.H. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis Dec 2008, 14(12):1660-1666.
25. Harvey R.F., Bradshaw J.M. A simple index of Crohn's disease activity. Lancet 1980, 1:514.
26. Focetria® prescribing information 2009, Novartis Vaccines & Diagnostics, Siena, Italy.
27. Frasca D., Diaz A., Romero M., Phillips M., Mendez N.V., Landin A.M., et al. Unique biomarkers for B cell function predict the serum response to pandemic H1N1 influenza vaccine. Int Immunol Mar 2012, 24(3):175-182. [Epub 2012 Jan 25].
28. McElhaney J.E., Meneilly G.S., Lechelt K.E., Beattie B.L., Bleackley R.C. Antibody response to wholevirus and split-virus influenza vaccines in successful ageing. Vaccine 1993, 11(10):1055-1060.
29. EMEA Committee for Human Medicinal products Note for Guidance on Harmonization Of Requirements for Influenza Vaccines, CPMP/BWP/214/96.
30. EMEA Committee for Human Medicinal products Guideline on Influenza Vaccines prepared from Viruses with the Potential to cause a Pandemic and intended for Use outside of the Core Dossier Context EMEA/CHMP/VWP/263499/2006.
31. Rahier J.F., Moutschen M., Van Gompel A., Van Ranst M., Louis E., Segaert S., et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) Oct 2010, 49(10):1815-1827.
32. Chalmes A., Scheifele D., Ptterson C., Williams D., Weber J., Shuckett R., et al. Immunization of patients with rheumatoid arthritis against influenza : a study of vaccine safety and immunogenicity. J Rheumatol 1994, 21:1203-1206.
33. Kubota T., Nii T., Nanki T., Kohsaka H., Harigai M., Komano Y., et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007, 17:531-533.
34. Fomin I., Caspi D., Levy V., Varsano N., Shalev Y., Paran D., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis Feb 2006, 65(2):191-194. [Epub 2005 Jul 13].
35. Kapetanovic M.C., Saxne T., Nilsson J.A., Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) Apr 2007, 46(4):608-611. [Epub 2006 Nov 18].
36. Aikawa N.E., Campos L.M., Silva C.A., Carvalho J.F., Saad C.G., Trudes G., et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012 Jan, 39(1):167-173. [Epub 2011 Nov 15].
37. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol Feb 2007, 34(2):272-279.
38. German IBD Study Group Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis. Dtsch Med Wochenschr May 2011, 136(18):939-943.
39. Lisotti A., Roda G., Brillanti S., Roda E. Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations. Dig Liver Dis Dec 2010, 42(12):909-910. [Epub 2010 Apr 24].
40. Rahier J.F., Papay P., Salleron J., Sebastian S., Marzo M., Peyrin-Biroulet L., et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut Apr 2011, 60(4):456-462. [Epub 2011 Jan 26].
41. Melmed G.Y., Agarwal N., Frenck R.W., Ippoliti A.F., Ibanez P., Papadakis K.A., et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol Jan 2010, 105(1):148-154. [Epub 2009 Sep 15].